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1  | INTRODUC TION
Haploinsufficiency of the melanocortin‐4 receptor (MC4R) in hu‐
mans is the most common monogenic cause of severe obesity, 
accounting for up to 5% of cases.1,2 The composite prevalence of 
obesity‐causing deleterious alleles in the human population has 
been demonstrated to be approximately 1 in 1500,3 and a detailed 
clinical picture of the syndrome has been reported.4,5 Remarkably, 
the syndrome is virtually identical to that reported for the mouse6‐8 
with increased adipose mass, lean mass, linear growth, hyperinsuli‐
naemia and severe hyperphagia. Genome‐wide association studies 
have also identified single nucleotide polymorphims adjacent to the 
MC4R gene that are associated with obesity.9‐11 These noncoding 
changes also support the notion that small changes in the expression 
level or activity of the MC4R may impact adiposity. Humans with 
haploinsufficiency, or even homozygous null status at the MC4R, are 
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Energy stores in fat tissue are determined in part by the activity of hypothalamic 
neurones expressing the melanocortin‐4 receptor (MC4R). Even a partial reduction in 
MC4R expression levels in mice, rats or humans produces hyperphagia and morbid 
obesity. Thus, it is of great interest to understand the molecular basis of neuromodu‐
lation by the MC4R. The MC4R is a G protein‐coupled receptor that signals effi‐
ciently through GαS, and this signalling pathway is essential for normal MC4R function 
in vivo. However, previous data from hypothalamic slice preparations indicated that 
activation of the MC4R depolarised neurones via G protein‐independent regulation 
of	the	ion	channel	Kir7.1.	In	the	present	study,	we	show	that	deletion	of	Kcnj13 (ie, the 
gene	encoding	Kir7.1)	specifically	from	MC4R	neurones	produced	resistance	to	mel‐
anocortin peptide‐induced depolarisation of MC4R paraventricular nucleus neurones 
in brain slices, resistance to the sustained anorexic effect of exogenously adminis‐
tered melanocortin peptides, late onset obesity, increased linear growth and glucose 
intolerance.	Some	MC4R‐mediated	phenotypes	appeared	 intact,	 including	Agouti‐
related peptide‐induced stimulation of food intake and MC4R‐mediated induction of 
peptide YY release from intestinal L cells. Thus, a subset of the consequences of 
MC4R	signalling	in	vivo	appears	to	be	dependent	on	expression	of	the	Kir7.1	channel	
in MC4R cells.
K E Y W O R D S
Kcnj13,	Kir7.1,	MC4R,	melanocortin‐4	receptor,	obesity
2 of 14  |     ANDERSON Et Al.
relatively normal outside of the obesity syndrome, with only mild 
hypotension	and	hyperinsulinaemia	being	reported.	Another	unique	
feature of the central melanocortin system are the gene dosage ef‐
fects for MC4R,8,12 a highly unusual finding for G protein‐coupled 
receptor signalling systems.
Thus, the MC4R is a well‐validated target for the treatment of 
common obesity8,9 and cachexia.13‐16	Other	studies	suggest	poten‐
tial applications in diabetes7,17,18 and the metabolic syndrome,19,20 
depression‐related anorexia and anhedonia,21 and obsessive‐com‐
pulsive disorder.22 The MC4R appears to be at the heart of the 
adipostat, in that administration of melanocortin agonists inhibits 
food intake12 and increases energy expenditure.23 Chronic ad‐
ministration of potent melanocortin agonists produces significant 
weight loss in model systems, from rodents to primates.24 However, 
clinical trials of potent small molecule orthosteric agonists of the 
MC4R have failed as a result of target‐mediated pressor effects. 
Despite	the	target‐mediated	pressor	response	resulting	from	most	
melanocortin agonists, two peptide analogues of the native MC4R 
ligand, α‐melanocyte‐stimulating hormone (α‐MSH), have been 
demonstrated to cause weight loss without a pressor response.24‐27 
One	of	these	compounds,	setmelanotide,	has	been	used	success‐
fully in a clinical trial in two patients with compound heterozygous 
mutations	 in	 pro‐opiomelanocortin	 (POMC),	 the	 preprohormone	
precursor for α‐MSH,24 and in a clinical trial in patients with ho‐
mozygous mutations in the gene encoding the leptin receptor.28 
There are no data available explaining why some MC4R agonists 
are capable of inducing weight loss without the target‐mediated 
pressor response, although biased agonism must be considered in 
the event that multiple signalling pathways are activated down‐
stream of MC4R.
In	 this	 regard,	 it	 is	 already	 appreciated	 that	 MC4R	 exhibits	
different signalling modalities on the cellular level in vivo. The 
MC4R couples to GαS in all cells tested, and it has been demon‐
strated that deletion of GαS from MC4R neurones recapitulates 
the phenotype seen in MC4R knockout mice.29 However, the 
complexity of MC4R signalling in vivo is also clear. α‐MSH ac‐
tivates MC4R positive intermediolateral nucleus neurones via a 
putative nonspecific cation channel,30 whereas it inhibits MC4R 
neurones in the dorsal motor nucleus of the vagus nerve via ac‐
tivation	of	a	KATP channel.
31 Recently, using a hypothalamic slice 
preparation in the mouse, we demonstrated that α‐MSH appears 
to depolarise and activate MC4R neurones in the paraventricular 
nucleus	(PVN)	via	a	G	protein‐independent	mechanism	involving	
inhibition	of	the	inward	rectifier	channel	Kir7.1.32 This is a highly 
unusual	finding,	requiring	further	validation	in	vivo.	Furthermore,	
a better understanding of the role(s) of variant MC4R signalling 
modalities in vivo might lead to a rationale pharmacological ap‐
proach for the development of small molecule biased agonists of 
MC4R that could discriminate between weight loss and pressor 
activities.	Aiming	toward	these	two	goals,	we	specifically	deleted	
the	inward	rectifier	Kir7.1	from	MC4R	cells	in	the	mouse	and	con‐
ducted pharmacological and physiological studies on the result‐
ing animals.
2  | MATERIAL S AND METHODS
2.1 | Mouse strains and genotyping
We used promoter‐driven, knockout‐first, Kcnj13 targeted selec‐
tion	clones	from	the	Knock‐Out	Mouse	Project	(KOMP)	Repository	
at	 UC	 Davis	 (Davis,	 CA,	 USA)	 for	 the	 generation	 of	 transgenic	
mice. Embryonic stem cell clones expressing the mutant allele 
Kcnj13tm1a(KOMP)wtsi were expanded at Vanderbilt’s Transgenic 
Mouse/ES	 Cell	 Shared	 Resource	 (TMESCSR,	 Nashville,	 TN,	 USA),	
where	chimeric	mice	were	generated	on	the	C57BL/6N	background.	
Germ line transmission was confirmed by crossing chimeric male 
mice	 to	 wild‐type	 C57BL/6N	 females.	 Genotyping	 confirmed	 the	
presence of the mutant allele, Kcnj13tm1a(KOMP)wtsi, in progeny. This 
allele	 also	 carries	 an	 En2	 splice	 acceptor	 sequence	 and	 a	 poly‐A	
transcription termination signal, which disrupts Kcnj13 gene func‐
tion.	Following	the	KOMP	breeding	strategy	for	mutant	allele	gen‐
eration, Kcnj13tm1a(KOMP)wtsi mice were bred to mice expressing the 
recombinase flippase to generate the Kcnj13tm1c(KOMP)wtsi allele. The 
expression of flippase recombinase excised the promoter‐driven 
Neo	cassette,	converting	allele	tm1a into conditional mutant allele 
tm1c. Mutant Kcnj13tm1c(KOMP)wtsi mice were mated to sibling mice to 
build a colony of Kcnj13tm1c mice (referred to as Kcnj13 fl/fl mice). The 
Kcnj13 fl/fl	colony	was	crossed	with	a	MC4R‐t2A‐Cre	Tg/+	line	(kindly	
provided	 by	 Dr	 Bradford	 Lowell,	 Beth	 Israel	 Deaconess	 Medical	
Center,	Boston,	MA)	to	generate	a	MC4R	cell‐specific	Kcnj13 knock‐
out experimental animal (referred to as Kcnj13ΔMC4RCre). This al‐
lele is referred to as Kcnj13tm1d	 in	KOMP	nomenclature.	All	mouse	
lines	 were	 maintained	 on	 a	 C57BL/6NJ	 background	 with	 annual	
backcrosses	to	wild‐type	C57BL/6NJ	mice	(Jax	Stock	No.	005304;	
Jackson	Laboratory;	Sacramento,	CA,	USA).
Mc4r‐tau‐Sapphire mice for electrophysiological studies were 
obtained	from	the	Jackson	Laboratory	(Jax	Stock	No.	008323).
Primers	 for	 genotyping	 Kcnj13fl/fl	 or	 Kcnj13+/+ alleles were: 
Kcnj13_ttR	 CCAGAGGGTGAGGCTTATAATTTGTGC	 and	 Kcnj13_F	
GGTCAGTGAGATATGGCCTAGTGGG.
2.2 | Mouse handling
All	mice	were	housed	under	standard,	infection–free	housing	condi‐
tions under a 12:12 hour dark cycle at 25°C. The strictly pathogen‐
free quality of the mouse colonies was maintained through quarterly 
serology, quarterly histopathologic examinations, as well as daily 
veterinarian monitoring of the general health and welfare of animals. 
Male and female mice were used for these experimental procedures. 
Mice were weaned at 4 weeks of age and maintained with four or 
five mice per cage, unless the animals were used for feeding stud‐
ies.	Animals	used	 in	 feeding	analysis	were	singly	housed	 for	acute	
studies and dually housed for long‐term feeding studies. Unless oth‐
erwise	described,	all	mice	were	fed	a	standard	chow	diet	(Lab	Diet;	
Purina,	 St	 Louis,	 MO,	 USA;	 S‐5LOD:	 13.5	kcal%	 fat,	 32.98	kcal%	
protein,	 56.7	kcal%	 carbohydrate).	 Diet‐induced	 obesity	 was	 pro‐
moted	 by	 a	 high‐fat	 diet	 (HFD)	 (Research	 Diets,	 New	 Brunswick,	
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NJ,	USA;	D12492:	60	kcal%	 fat,	20	kcal%	protein,	20	kcal%	carbo‐
hydrate).	Post‐mortem	studies	were	conducted	by	giving	animals	a	
dose of 5 mg kg‐1 tribromoethanol to deeply anaesthetise the mice 
before being killed via decapitation. Tissues of interest were rapidly 
excised	and	flash	frozen	by	liquid	nitrogen.	All	procedures	were	car‐
ried	out	with	approval	 from	the	 Institutional	Animal	Care	and	Use	
Committee of Vanderbilt University Medical Center.
2.3 | Hypothalamic slice electrophysiology
Mc4r‐tau‐Sapphire mice, backcrossed onto the C57BL/6J back‐
ground, were previously characterised by dual immunohistochem‐
istry and in situ hybridisation to confirm that green fluorescent 
protein	(GFP)‐positive	neurones	in	the	PVN	expressed	MC4R	RNA.33 
Randomly	 selected	 MC4R‐GFP	 male	 and	 female	 mice	 in	 the	
Kcnj13ΔMC4RCre or Kcnj13+/+;MC4RCre background, 8‐16 weeks of 
age, were deeply anaesthetised with isoflurane before decapitation. 
The brain was entirely removed and immediately submerged in ice‐
cold,	gassed	 (95%	O2,	5%	CO2)	artificial	cerebrospinal	 fluid	 (aCSF),	
containing (in mmol L‐1):	 126.2	 NaCl,	 3.1	 KCl,	 2	 CaCl2, 1 MgCl2, 
1	NaH2PO4,	26.2	NaHCO3, 10 glucose and 11 sucrose (320 mosm kg
‐1, 
pH	7.39	when	gassed	with	95%	O2,	5%	CO2 at room temperature). 
Brain blocks containing hypothalamus were made by trimming whole 
brains when the brains were immersed in oxygenated, near‐freezing 
aCSF	and	glued	to	a	dental‐cement	cast	customised	to	 the	size	of	
the block mounted on a plate with adjustable angle. Brain slices of 
200 μm in thicknesses were then cut at an angle range between 44° 
and 49° in reference to the horizontal plane and transferred to a glass 
beaker	 containing	 oxygenated	 aCSF	 at	 31°C.	 After	 an	 incubation	
period lasting at least 1 hour, a slice was transferred to a recording 
chamber (approximately 2.0 mL in volume), then submerged and im‐
mobilised with nylon strands drawn taut across a C‐shaped platinum 
wire (outer diameter 1 mm) and perfused with warmed (31‐32°C) 
oxygenated	aCSF	at	a	rate	of	2‐3	mL	min‐1.	Enhanced	GFP‐fluores‐
cent neurones were unambiguously identified and patched using 
combined epifluorescence and infrared‐differential interference 
contrast	(IR‐DIC)	optics.	Fluorescent	neurones	of	healthy	IR‐DIC	ap‐
pearance but of every level of fluorescence brightness were chosen 
for	electrophysiological	recordings.	Drugs	were	added	to	aCSF	and	
bath applied to the slice via the perfusion system for extracellular 
application. The small volume of the recording chamber relative to 
the flow rate assured a complete exchange of solution occurring in 
less than 1 minute. The persisting effects of a peptide were there‐
fore a result of prolonged effects rather than a slow wash out.
In	 the	 present	 study,	 whole‐cell	 patch‐clamp	 recordings	 were	
used to obtain information about action potential firing activity, 
as well as membrane potentials and currents. Unless stated other‐
wise, whole‐cell recordings were performed using patch pipettes of 
3.4 MΩ to 5 MΩ resistance when filled with a solution containing 
(in mmol L‐1);	125	K	gluconate,	8	KCl,	4	MgCl2,	10	Hepes,	5	NaOH,	
4	Na2ATP,	0.4	Na3GTP,	5	Na2‐creatine phosphate, 7 sucrose and 7 
KOH,	 which	 resulted	 in	 a	 approximate	 pH	7.23	 and	 osmolality	 of	
295‐300 mosmol kg‐1. The permeability of the α‐MSH regulated 
channels	was	investigated	by	replacing	K	gluconate	and	KCl	with	130	
RbCl	and	4	KCl,	but	otherwise	similar	conditions.	The	examination	
of effects of Mg2+‐free internal solution on the α‐MSH‐induced cur‐
rent	was	conducted	in	voltage‐clamp	mode	from	PVN	neurones	held	
at	 −55	mV.	 The	Mg2+‐free internal solution contained (in mmol L‐1) 
103	K	gluconate,	30	KCl,	10	Hepes‐KOH,	0.5	CaCl2	and	5.5	EDTA‐
KOH	 (pH	7.23),	 with	 osmolality	 304	mosmol	kg‐1.	 The	 ATP	 free	
solution contained (in mmol L‐1)	83	K	gluconate,	30	KCl,	10	Hepes‐
KOH,	0.5	CaCl2, 4 MgCl2	and	5.5	EGTA‐KOH	(pH	7.2),	with	osmo‐
lality 298 mosmol kg‐1.	Neuronal	integrity	was	assessed	by	all	of	the	
following:	small	holding	current	 (≤30	pA	at	−70	mV)	when	voltage‐
clamped, large amplitude rebound spikes, the ability to fire and a 
lack of obvious morphological deterioration (ie, lack of blebbing and 
nucleus not visually present).
To quantify the action potential firing and amplitude of depolari‐
sation induced by α‐MSH, current‐clamp recordings were performed 
in continuous mode when the membrane potential of neurones was 
held	between	−55	and	−60	mV	to	prevent	continuous	spontaneous	
action potential firing. The firing frequency and membrane poten‐
tial of neurones was measured during a 3‐minute period before 
the application of the peptides, and for another 3‐minute period 
7‐11 minutes after administration of peptide, with the results being 
compared.
Data	were	acquired	at	10	kHz	using	a	MultiClamp	700A	ampli‐
fier	 (2000×	 gain,	 −3	dB	 filter	 frequency	 5	kHz)	 and	 clampex, ver‐
sion	10.0.1	(Axon	Instruments,	Union	City,	CA,	USA).	prism, version 
5.0	(Graphpad	Software,	 Inc.,	San	Diego,	CA,	USA)	and	excel 2010 
(Microsoft	Corp.,	Redmond,	WA,	USA)	were	used	for	data	analysis.	
Statistical tests used included the paired t test, when examining the 
response of the same neurones before and after treatment with a 
compound, and the unpaired t test when comparing the responses 
of different sets of neurones.
2.4 | Fast‐induced refeeding
Age	 and	 litter	 matched	 male	 and	 female	 mice	 were	 used	 for	 the	
present study as obtained from young (not shown) and mature 
(35‐45 weeks of age) cohorts. Studies were repeated at least three 
times	 across	 multiple	 cohorts.	 One	 week	 before	 the	 study,	 mice	
were singly housed and accustomed to handling with i.p. injections 
of 100 μL of saline when provided with ab lib. standard chow and 
water.	One	day	before	the	study,	mice	were	moved	to	clean	cages	
with fresh bedding to minimise coprophagia. Mice were food de‐
prived for 16‐24 hours before the drug was administered at the be‐
ginning of the dark cycle.
Experiments were blinded; drug compounds were prepared and 
coded on the morning of the injections by an individual who would 
not be conducting the experiment. The randomly selected experi‐
mental groups consisted of animals that were given vehicle (saline) or 
10.0 mg kg‐1	of	the	melanocortin	agonist	LY2112688	(LY).	For	repeated	
studies, animals rested at least 7 days between fasting periods and 
opposite treatments were given. The numbers needed to achieve sig‐
nificant inhibition of food intake by a melanocortin compound versus 
4 of 14  |     ANDERSON Et Al.
saline	were	based	on	prior	experience.	Food	 intake	was	measured	at	
multiple time points after injection, beginning at 2 hours and extending 
as	far	as	40	hours	after	injection.	In	viral	knockdown	studies,	a	ground	
feeding canister with a wire mesh bottom was used, rather than the 
cage hopper. Mice were accustomed to the presence of the canister in 
their cage for 1 week before the experiment. The reduced accessibility 
of this apparatus is reflected by the reduced chow consumption in viral 
knockdown mice compared to cell‐specific genetic deletion mice stud‐
ies.	Statistical	significance	was	established	using	two‐way	ANOVA	and	
Tukey’s post‐hoc test. P < 0.05 was considered statistically significant.
2.5 | Short hairpin RNA (shRNA) lentiviral 
design and hypothalamic injection
Mouse Kcnj13	 shRNA	 and	 scramble	 shRNA	 (sc	 shRNA)	 were	
constructed	 using	 the	 vector	 pSico	 (Addgene,	 Cambridge,	 MA,	
USA).	Kcnj13	 shRNA	plasmid	 (TRCN0000262099)	 (clone	#99)	 (see	
Supporting	information,	Figure	S3)	was	from	Sigma	(St	Louis,	MO,	USA)	
with	 sequence:	 CCGGCGCCTTACTTGCCATACAAATCTCGAGAT 
TTGTATGGCAAGTAAGGCGTTTTTG.	 Scramble	 shRNA	 (plasmid#	
1864)	 was	 purchased	 from	 Addgene.	 Scramble	 shRNA	 construct	
in	 pLKO.1	 vectors	 was	 subcloned	 into	 pLL3.7	 (plasmid	 #:11795;	
Addgene),	 which	 also	 encodes	 GFP.	 pLL3.7	 plasmid	 with	 shRNA	
(scramble vs. Kcnj13). Kcnj13	 shRNA	sequence	 (see	Supporting	 in‐
formation,	Figure	S3)	was	cloned	into	pLKO.1	expressing	mCherry.
293T cells were transfected with 12.6 μg of plasmids containing 
the	shRNA	(scramble	vs.	Kcnj13)	and	6.3	μg each of the following plas‐
mids:	pRSV‐Rev,	pVSVG	and	pMDLp/g	 (gift	 from	Dr	Roger	Colbran,	
Vanderbilt	 University	 School	 of	 Medicine,	 Nashville,	 TN)	 using	
Lipofectamine	2000	(Invitrogen,	Carlsbad,	CA,	USA)	on	15	cm	dishes.	
Some 96 hours post‐transfection, culture medium from five 15 cm‐
plates	per	shRNA	clone	were	collected,	and	filtered	through	a	0.45‐μm 
filter. Viral particles were isolated by ultracentrifugation at 4°C and 
76 800 g for 2 hours. The pellet was resuspended in sterile phosphate‐
buffered	saline,	aliquoted	and	frozen	at	−80°C	until	further	use.
Viral titre was quantified as follows: 100 000 293T cells were 
plated on 24‐well plates. Cells were transduced by ten‐fold serial 
dilutions of the viral particles with a dilution range between 1:10 
and 1:105	 using	 polybrene.	 GFP	 (for	 scramble	 shNA)	 or	 mCherry	
(for	shRNA	against	Kcnj13) positive cells were counted in triplicate. 
Purified	 lentivirus	 suspended	 in	550‐600	nL	of	 aCSF	was	 injected	
bilaterally	and	infused	over	15	minutes	into	the	PVN	using	a	stereo‐
tactic frame and the coordinates of 0.82 mm posterior to bregma, 
0.31 mm lateral to the midline of the brain and 4.68 mm below the 
surface of the skull, via a 26‐gauge guide cannula and a 33‐gauge in‐
ternal	injector	(Plastics	One,	Roanoke,	VA,	USA)	connected	to	a	2‐μL 
Hamilton syringe.
2.6 | Cannulation surgery for i.c.v. injection
To	 investigate	 the	 effect	 of	 i.c.v.	 injection	 of	 AgRP,	 mice	 were	
anaesthetised	with	isoflurane	and	a	stainless‐steel	cannula	(Plastics	
One)	was	surgically	implanted	into	the	right	lateral	ventricle	using	
the stereotaxic coordinates of 0.46 mm posterior to the bregma, 
1.0 mm lateral to the midline and 2.2 mm below the surface of the 
skull. Mice were allowed to recover for approximately 5 days at 
the same time as monitoring food intake and body weight with ac‐
climatisation to handling and manipulation of the dummy cannula. 
After	recovery,	cannula	placement	was	verified	by	 injecting	10	ng	
of	angiotensin	II	 (Sigma)	diluted	in	0.5 μL	of	sterile	saline.	Animals	
that did not exhibit a drinking response within 30 minutes were 
excluded	 from	the	study.	One	day	 later,	experimental	procedures	
were	initiated	during	the	light	cycle.	Peptides	(AgRP83‐132) or vehicle 
were infused in a volume of 0.5 μL over a 1‐minute period with a 
2.0‐μL	Hamilton	syringe	(Plastics	One)	coupled	to	an	injection	can‐
nula	via	polyethylene	tubing.	After	injection,	the	injector	was	kept	
in	place	for	1	minute	to	ensure	diffusion	from	the	injector	tip.	Food	
intake and body weight was monitored after injection. When the 
experimental procedures concluded, cannula placement was also 
confirmed histologically.
2.7 | Plasma hormone measurements
Male and female experimental mice (Kcnj13ΔMC4RCre; Kcnj13 fl/fl) 
aged 25‐27 weeks were acclimated to scruffing and injections for 
up to 5 days prior to blood collection. The day of the study, post‐
prandial	plasma	peptide	YY	(PYY)	was	reduced	to	baseline	levels	by	
a 6‐hour daytime fast. Mice were randomly selected to receive an 
i.p. injection of vehicle (saline) or 5 mg kg‐1 LY2112688 in volumes 
of 100‐200 μL	in	accordance	with	body	weight.	Numbers	were	cho‐
sen based on prior experience suggesting that significance can be 
achieved	with	six	animals	per	treatment.	At	10	minutes	post‐injec‐
tion, approximately 200 μL of blood was collected via submandibular 
bleeding in conscious mice or by decapitation under anaesthesia for 
trunk bleeding. Blood was collected into vials containing appropriate 
volumes	of	EDTA	and	protease	inhibitor	cocktail	for	mammalian	tis‐
sues	(P8340;	Sigma)	to	prevent	degradation	of	PYY	and	kept	on	ice.	
Upon collection of all blood samples, the vials were spun at 3000 g 
for	30	minutes	at	4°C.	Plasma	was	removed	and	spun	at	10	000	g for 
1	minute	at	4°C	to	pellet	remaining	blood	cells.	Plasma	was	frozen	
at	−80°C	until	PYY	was	assayed.	Plasma	hormones	were	assayed	in	
10‐μL	duplicate	samples	using	the	MilliplexMAP	Mouse	Metabolic	
Hormone	Magnetic	 Bead	 Panel	 Immunoassay	 (MMHMAG‐44K	 1‐
plex	kit	for	total	PYY;	Merck,	Darmstadt,	Germany),	with	undiluted	
plasma	to	detect	PYY	(total).	The	assay	was	read	on	a	Luminex	100	
analyser	 (Luminex	 Corp.,	 Austin,	 TX,	 USA).	 The	 results	were	 ana‐
lysed against a standard curve and concentrations were determined 
using milliplex analyst, version 5.1 (Merck). Values were plotted and 
analysed using prism	(GraphPad	Software	Inc.,	San	Diego,	CA,	USA).	
Statistical analyses were conducted using multiple t tests.
2.8 | Growth phenotyping
Male and female mice were dually housed with same sex, same gen‐
otype animals of similar weight to collect weekly food intake (stand‐
ard	 chow	 or	 diet‐induced	 obesity	 [DIO])	 and	 growth	 data.	Mouse	
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lean	and	 fat	mass	body	composition	was	obtained	by	NMR	 (mq10	
Minispec;	Bruker,	Billericia,	MA,	USA).
2.9 | Metabolic studies
Glucose tolerance testing was conducted as described previously.34 
Three days prior to the glucose tolerance test (GTT), the body com‐
position was obtained to determine the lean body mass. Mice were 
then	 habituated	 to	 consecutive,	 daily	 handling	 sessions.	 On	 the	
study day, mice were fasted for 6 hours (from 9:00 am to 3:00 pm). 
Mice were scruffed to obtain a basal glucose read by tail nick, then 
injected	with	1	(DIO)	to	2	(chow)	mg	kg‐1 lean mass dose of glucose in 
sterile phosphate‐buffered saline. Tail vein bleeding was performed 
at 15, 30, 45 60, 90 and 120 minutes after the injections. Glucose 
readings were obtained by tail vein bleeds at the times indicated. 
Glucose	was	measured	using	Aviva	PLUS	Glucose	test	Strips		(Roche	
Diagnostics).	Lean	mass	was	determined	by	a	NMR	body	composi‐
tion scan (mq10 Minispec; Bruker). Repeated sampling by tail vein 
bleeding was carried out at intervals at least 1 week apart to allow 
for a complete recovery from blood loss. The area under the curve 
was calculated using the trapezoidal rule.
2.10 | Statistical analysis
Sample size for growth curve studies was chosen using the power 
equation (α < 0.05, β = 0.1, Δμ = 25% σ = 5), whereas sample sizes for 
the remaining studies were estimated based on previous publications. 
All	 statistical	 tests	were	 conducted	 using	 prism, version 6 (Scientific 
Software,	La	Jolla,	CA,	USA).	Data	are	presented	as	the	mean	±	SE	of	
the mean. P < 0.05 was considered statistically significant. Experimental 
performers were generally blinded for the initial studies and partially 
blinded for genotype identity for the repeated studies. Experiments 
were repeated at least three times with age‐ and litter‐matched animals 
across the experimental and control groups.
3  | RESULTS
3.1 | Global and tissue‐specific deletion of Kcnj13
To	analyse	 the	potential	 roles	of	Kir7.1	 in	MC4R	neurones	 in	vivo,	
we developed a versatile, transgenic mouse strategy (see Supporting 
information,	 Figure	 S1)	 using	 the	 KOMP	mutant	 allele	 repository.	
After	 germ	 line	 transmission,	 the	 first	 generation	 mutant	 was	 a	
homozygous, global null mouse (Kcnj13KO).	As	previously	 reported	
using a Velocigene method, we confirmed that the Kcnj13KO resulted 
in	early	(P0)	postnatal	lethality	(see	Supporting	information,	Figure	
S2).35	Pathological	analyses	indicated	retardation	of	lung	and	kidney	
development and failure to suckle as likely sources of lethality. We 
next derived a floxed line by crossing these animals with a flippase 
recombinase	 transgenic	 C57Bl/6NJ	 line.	 Mice	 expressing	 Kcnj13 
flanked	by	loxP	sequences	(Kcnj13 fl/fl) were confirmed by genotyp‐
ing. Tissue‐specific Kcnj13 knockout mice were then derived using 
the	 Cre‐loxP	method.	Kcnj13 fl/fl mice were crossed with mice ex‐
pressing the alleles Kcnj13 fl/fl and MC4R‐t2A‐Cre Tg/+ (MC4RCre) to 
generate a MC4R cell‐specific Kcnj13 knockout experimental animal, 
hereafter referred to as Kcnj13ΔMC4RCre (Table 1).
3.2 | Defective α‐MSH‐induced depolarisation of 
MC4R PVN neurones from Kcnj13ΔMC4RCre mice
Kcnj13 is expressed at low levels in the sparsely distributed MC4R 
neurones	in	the	CNS.32 Thus, it is challenging to demonstrate tissue‐
specific deletion of Kcnj13	using	mRNA	expression.	However,	we	had	
previously	 developed	 a	 functional	 assay	 of	 Kir7.1	 in	 a	 hypothalamic	
slice preparation.32	In	this	assay,	Kir7.1	was	demonstrated	pharmaco‐
logically to be required for α‐MSH‐induced depolarisation of MC4R 
neurones in the paraventricular nucleus of the hypothalamus. We 
chose	to	use	 this	assay	 to	 test	 for	Kir7.1	activity	 in	MC4R	neurones	
in Kcnj13ΔMC4RCre	 mice.	 To	 characterise	 the	 necessity	 of	 Kir7.1	 for	
α‐MSH‐induced depolarisation of MC4R‐expressing neurones within 
the	 PVN,	 electrophysiological	 slices	 were	 prepared	 from	 control	
Kcnj13+/+;MC4RCre and Kcnj13ΔMC4RCre mice, in which MC4R neurones 
are	transgenically	labelled	with	GFP.	Whereas	a	250	nmol	L‐1 bath ap‐
plication of α‐MSH	successfully	depolarised	PVN	MC4R	neurones	in	
recordings	from	control	mice	(Figure	1A),	depolarisation	did	not	occur	
in	recordings	from	PVN	MC4R	neurones	from	Kcnj13ΔMC4RCre mice 
(Figure	1B).	 These	 data	 show	 the	 absence	 of	 a	 characterised	 Kir7.1	
response in Kcnj13ΔMC4RCre mice, thereby supporting the argument 
that	Kir7.1	is	not	expressed	in	mutant	Kcnj13ΔMC4RCre	PVN	neurones,	
and	 that	Kir7.1	 is	 required	 for	α‐MSH‐induced depolarisation in this 
electrophysiological	slice	assay.	Figure	1(B)	also	shows	representative	
traces from individual MC4R neurones in each genotype, as well as the 
membrane potential of MC4R neurones from each genotype, before 
and after α‐MSH treatment.
3.3 | Defective anorexic response to melanocortin 
peptides in Kcnj13ΔMC4RCre mice
Because	 the	 absence	 of	 Kir7.1	 disrupted	 α‐MSH‐induced neu‐
ronal	 depolarisation	 in	 PVN	 MC4R	 neurones	 in	 an	 ex	 vivo	 slice	
Mouse Genome Informatics name Common name
Global knockout C57BL/6J‐Kcnj13tm1a(KOMP)Wtsi Kcnj13KO
Floxed	allele C57BL/6J‐Kcnj13tm1c(KOMP)Wtsi Kcnj13 fl/fl
Cell‐specific knockout C57BL/6J‐Kcnj13tm1d(KOMP)Wtsi Kcnj13ΔMC4RCre
Cre driver Tg: C57BL/6J‐MC4R‐t2a‐Cre Kcnj13+/+;MC4RCre
TA B L E  1  Nomenclature	of	mouse	
strains used in the present study
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preparation, we hypothesised that feeding behaviour in response 
to melanocortin agonist administration might also be adversely af‐
fected. To investigate the physiological effect of an MC4R agonist 
on	MC4R	neurones	in	the	absence	of	Kir7.1	in	vivo,	we	administered	
the potent α‐MSH analogue, LY2112688 (LY), at the beginning of 
the dark cycle, after a 16‐24 hour fast, and measured food intake. 
Despite	the	powerful	drive	to	restore	energy	stores	resulting	from	
a state of nutritional deficit, LY2112688 blunted the fasting‐in‐
duced refeeding response in control genotype groups; however, in 
Kcnj13ΔMC4RCre	male	 (Figure	2A)	and	female	 (Figure	2B)	mice	the	
duration	of	LY2112688	action	was	reduced.	Notably,	from	3	hours	
post refeeding in males and 4 hours post refeeding in females to 
12	hours	 later,	mice	with	MC4R	 specific	 deletion	of	Kir7.1	 show	a	
significantly reduced anorectic response to LY2112688 compared to 
Kcnj13 fl/fl in males and Kcnj13 fl/fl or Kcnj13+/+;MC4RCre control groups 
in	females.	Additionally,	at	13	and	24	hours,	there	was	no	significant	
difference between the action of saline or LY2112688 administered 
to Kcnj13ΔMC4RCre males, whereas feeding in control Kcnj13 fl/fl ani‐
mals injected with LY2112688 remained suppressed.
The study paradigm was repeated using male mice following 
bilateral lentiviral Kcnj13	 shRNA	 knockdown,	 or	 administration	
of	 a	 scrambled	 control	 lentivirus	 in	 the	 PVN	 (sc	 shRNA).	 Three	
different	 lentivirus	 constructs	 designed	 to	 knockdown	 Kcnj13	
were	 purchased	 and	 tested	 for	 efficacy	 using	HEK293	 cells	 ex‐
pressing	Kcnj13	(see	Supporting	 information,	Figure	S3).	A	virus	
yielding >70% reduction in Kcnj13	mRNA	 levels	 (clone	#99)	was	
selected	for	these	experiments.	After	3	weeks	of	recovery,	mice	
were acclimated to handling and injection before beginning the 
fast‐induced	 refeeding	 study	 (Figure	2C).	 Similar	 to	 genetic	 de‐
letion	of	Kir7.1,	viral	knockdown	of	Kir7.1	exclusively	in	the	PVN	
also reduced the duration of the anorectic activity of LY2112688. 
LY2112688 was no longer effective at reducing food intake com‐
pared	 to	saline	 in	Kir7.1	knockdown	animals	 from	12	hours	post	
refeeding up to 40 hours. Conversely, LY2112688 significantly 
reduced	chow	consumption	in	mice	with	intact	Kir7.1	for	the	du‐
ration of the study. Successful targeting and delivery of Kcnj13 
shRNA	or	sc	shRNA	lentiviral	vectors	were	confirmed	by	GFP	ex‐
pression	 localised	to	the	PVN	in	post‐mortem	mice	 (not	shown).	
Taken	 together,	 these	 data	 show	 that	 Kir7.1	 expression	was	 re‐
quired for the extended duration of anorectic response to a me‐
lanocortin peptide.
We	 have	 previously	 shown	 the	 role	 of	 Kir7.1	 in	mediating	 a	
G protein‐independent MC4R response in both hypothalamic 
slices	 and	 in	 cells	 transfected	 with	 MC4R	 and	 Kir7.1.32 These 
electrophysiological and pharmacological experiments also 
demonstrated	 that	 AgRP	 appeared	 to	 open	 Kir7.1	 channels	 in	
a MC4R‐dependent manner.32	 To	 determine	 whether	 Kir7.1	
is	 necessary	 for	 AgRP‐induced	 stimulation	 of	 food	 intake,	 we	
delivered	 i.c.v.	 AgRP	 to	mice	 in	 a	 fed	 state.	 Cannulas	were	 im‐
planted in the lateral ventricle of Kcnj13 fl/flKcnj13+/+;MC4RCre, and 
Kcnj13ΔMC4RCre male mice, and animals were allowed to recover 
for 5 days. Two days after a saline injection to establish baseline 
conditions,	2	nmol	of	the	peptide	AgRP	was	injected	i.c.v.	during	
the light cycle. We observed no significant difference in central 
AgRP‐induced	feeding	 initiation	or	duration	between	genotypes	
(see	Supporting	 information,	Figure	S4A),	 suggesting	 that	Kir7.1	
was	not	required	for	the	orexigenic	response	to	AgRP.	Likewise,	
all	genotypes	responded	to	AgRP	with	an	increase	in	body	weight	
in proportion to the increase in food intake (see Supporting in‐
formation,	 Figure	 S4B).	 There	 was	 no	 significant	 difference	 in	
change in body weight between genotypes.
3.4 | Normal melanocortin‐stimulated PYY release 
in Kcnj13ΔMC4RCre mice
Although	MC4R	is	expressed	in	many	brain	nuclei,	peripheral	ex‐
pression	has	 also	been	mapped.	Notably,	MC4R	 is	 expressed	 in	
enteroendocrine L cells, and peripheral administration of α‐MSH 
has been demonstrated to induce MC4R‐dependent release of 
PYY	 and	 GLP1	 from	 these	 cells.36 Thus, the function of MC4R 
on L cells can be assessed using an assay for increased plasma 
PYY	following	peripheral	administration	of	an	MC4R	agonist.	We	
next	examined	the	requirement	for	Kir7.1	in	MC4R‐mediated	PYY	
release	from	L	cells.	The	absence	of	Kir7.1	in	MC4R	cells	did	not	
interfere	with	 the	 release	of	 the	 satiety	 factor	PYY	 into	plasma	
(Figure	3).	Thus,	the	role	of	Kir7.1	in	MC4R	function	appeared	to	
be	important	in	neurones	of	the	PVN	but	not	enteroendocrine	L	
cells.
F I G U R E  1  Defective	α‐melanocyte‐stimulating hormone (α‐
MSH)‐induced depolarisation of melanocortin‐4 receptor (MC4R) 
PVN	neurones	in	Kcnj13ΔMC4RCre mice. Slice electrophysiology 
of	PVN	MC4R‐GFP‐positive	neurones	recorded	in	current	clamp	
with bath application of 250 nmol L‐1 α‐MSH.	A,	Recordings	
from Kcnj13+/+;MC4RCre;MC4R‐GFP	mice	in	response	to	vehicle	
or α‐MSH, showing that the induction of action potential 
differs significantly between and control and α‐MSH	in	bath.	A	
representative	depolarising	response	of	a	PVN	MC4R	neurone	is	
seen on the right. B, Recordings from Kcnj13ΔMC4RCre;MC4R‐GFP	
mice show no significant response to α‐MSH, P	=	0.11.	A	
representative	response	of	a	PVN	MC4R	neurone	is	seen	on	
the	right.	Bar	graph	represents	the	mean	±	SEM	of	15‐35	cells	
(***P < 0.0001, paired t	test).	DVm, membrane potential in millivolts 
(mV).	NS,	not	significant
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3.5 | Phenotypic characterisation of 
Kcnj13ΔMC4RCre mice
Global deletion of MC4R in the mouse can produce measurable 
increases in adipose mass as early as 5 weeks of age.8 To deter‐
mine	 the	 effects	 of	 Kir7.1	 ablation	 on	 MC4R	 signalling,	 we	 in‐
vestigated body weight, body composition, feeding behaviour 
and glucose tolerance in Kcnj13ΔMC4RCre and control Kcnj13 fl/fl, 
Kcnj13+/+;MC4RCre and Kcnj13+/+;MC4R+/+	mice.	At	20	weeks	of	age,	
we did not observe differences in body weight in the four strains 
maintained	 on	 normal	 mouse	 chow	 (Figure	4A,B).	 Moreover,	
when lean and fat mass accrual are compared in young 12 week 
old mice and mature mice, no significant difference was detected 
in	 lean	 or	 fat	mass	 between	 groups	 (Figure	4D‐G).	 However,	 by	
26 weeks of age in female mice and 50 weeks of age in male mice, 
Kcnj13ΔMC4RCre animals show significantly greater weight com‐
pared	to	all	three	control	strains	(Figure	4A,B).	One‐way	ANOVA	
showed that Kcnj13ΔMC4RCre male and female mice gained 
F I G U R E  2  Defective	anorexic	
response to melanocortin agonist 
LY2112688 in Kcnj13ΔMC4RCre mice. 
Feeding	response	in	dark	cycle	after	
i.p. injection of saline or LY2112688 in 
male	(A),	or	female	(B)	Kcnj13ΔMC4RCre, 
Kcnj13 fl/fl and/or Kcnj13+/+;MC4RCre, 
Kcnj13+/+;MC4R+/+ and male (C) Kcnj13 
shRNA	or	scamble	short	hairpin	RNA	
lentiviral knockdown mice following 
a 16‐24‐h fast. LY2112688 was 
administered at 10 mg kg‐1 (n = 4‐9 
per group, *P < 0.05, **P < 0.005, 
****P	<	0.0001,	two‐way	ANOVA	with	
multiple	comparisons	test).	NS,	not	
significant
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F I G U R E  3  Normal	melanocortin‐stimulated	plasma	peptide	YY	
(PYY)	release	in	Kcnj13ΔMC4RCre mice. Male and female C57BL/6J 
Kcnj13ΔMC4RCre and Kcnj13 fl/fl control mice were administered 
saline or saline containing 5 mg kg‐1	LY2112688	i.p.	Fifteen	
minutes following treatment, blood was collected and plasma was 
prepared.	Plasma	was	then	assayed	for	PYY	using	an	enzyme‐
linked	immunosorbent	assay	(Luminex).	Points	indicate	mean	PYY	
concentrations determined in duplicate from individual mouse 
serum samples; bars indicate means from multiple mice (n = 6‐7 per 
group, *P < 0.05, Student’s t test)
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F I G U R E  4   Late onset obesity develops in chow fed Kcnj13ΔMC4RCre	mice.	Growth	curves	on	chow	diet	of	(A)	male	and	(B)	female	
mice	interspersed	across	three	age	cohorts	from	9	to	63	weeks.	One‐way	ANOVA	shows	Kcnj13ΔMC4RCre male and female mice gained 
significantly	more	weight	over	the	time	course	than	the	control	genotypes.	C,	D,	Snout‐to	anus	length	of	euthanised	female	(C)	and	male	
(D)	Kcnj13ΔMC4RCre, Kcnj13 fl/fl, Kcnj13+/+;MC4RCre, and Kcnj13+/+;MC4R+/+ mice at the age of approximately 30 weeks. Each dot 
represents the snout‐anus distance of one individual animal (n = 6‐25 per group, **P < 0.005, ****P < 0.0001, multiple t test with Holm‐
Sidak	post‐hoc	test).	E,	Daily	chow	consumption	per	mouse	at	mouse	age	indicated	in	weeks.	One‐way	ANOVA	test	with	Tukey’s	multiple	
comparisons.	Absolute	fat	(F)	and	lean	(G)	mass	and	%fat	(H)	and	%lean	(I)	mass	body	composition	of	12‐,	22‐	and	28‐week‐old	female	mice.	
Multiple t	tests	with	Holms‐Sidak	multiple	comparison	test.	(J‐L)	Plasma	glucose	concentration	during	i.p.	glucose	tolerance	test	(IPGTT).	
Glucose (2 g kg‐1),	normalised	to	%	lean	body	mass,	was	administered	to	each	animal.	IPGTT	was	performed	after	6	h	of	daytime	fasting	
in	28‐week‐old	female	animals.	Comparison	of	the	difference	in	total	area	under	the	curve	(AUC)	shows	(K)	AUC	from	0	to	120	is	similar,	
whereas Kcnj13ΔMC4RCre mice differ significantly from control genotypes from (L) 45‐120 min. J, multiple t	tests,	(K‐L)	One‐way	ANOVA	
with multiple comparisons (n = 6‐12 per group, *P < 0.05, **P < 0.005, ***P < 0.0005, ****P < 0.0001)
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F I G U R E  5  Obesity	and	glucose	intolerance	in	Kcnj13ΔMC4RCre	mice	on	a	high‐fat	diet	(HFD).	Growth	curves	on	a	HFD	from	(A)	male	
and	(C)	female	mice	(n	=	7‐11	per	group,	Mixed	linear	effect	model	of	DIO	male	Kcnj13+/+;MC4RCre vs. Kcnj13 fl/fl P < 1.1 × 10‐6, female 
P < 2.2 × 10‐16. Kcnj13+/+;MC4RCre vs. Kcnj13ΔMC4RCre male P = 0.01, female P = 0.8) (*P < 0.05, **P < 0.005 via multiple Students t test 
Kcnj13+/+;MC4RCre vs. Kcnj13ΔMC4RCre).	Daily	HFD	consumption	of	(B)	male	and	(D)	female	mice.	One‐way	ANOVA	test.	E‐H,	Fat	and	
lean	mass	body	composition	of	male	(E‐F)	and	female	(G‐H)	on	chow	vs	HFD.	Two‐way	ANOVA	with	Tukey’s	multiple	comparison	test.	
(I‐L)	Plasma	glucose	concentration	during	i.p.	glucose	tolerance	test	(IPGTT).	Glucose	(1	g	kg‐1), normalised to % lean body mass, was 
administered	to	each	animal.	IPGTT	was	performed	after	8	h	of	daytime	fasting	in	mice	fed	HFD	for	5	months	in	(I)	male	and	(K)	female	
animals.	Comparison	of	the	percentage	difference	in	total	area	under	the	curve	(AUC)	shows	that	Kcnj13ΔMC4RCre differs significantly 
from control genotypes in (J) males and (L) females (n = 6‐8 per group, *P < 0.05, **P < 0.005, ***P	<	0.0005,	one‐way	ANOVA	with	Tukey’s	
multiple comparisons test)
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significantly more weight over the time course than the control 
genotypes.	No	significant	difference	was	observed	in	daily	chow	
consumption	between	groups	(Figure	4C).	Using	indirect	calorim‐
etry, no significant difference was observed in energy expendi‐
ture	among	the	four	strains	(data	not	shown).	At	28	weeks	of	age,	
female Kcnj13ΔMC4RCre mice weight were observed to have sig‐
nificantly more absolute and %fat mass compared to control geno‐
types	(Figure	4D,F),	whereas	lean	mass	was	unchanged	(Figure	4E).	
Both male and female 30 week old Kcnj13ΔMC4RCre animals also 
exhibited	 increased	 length	 relative	 to	 all	 controls	 (Figure	4C‐D),	
as	 is	 observed	 in	MC4RKO	mice	 and	 humans.	 The	%	 lean	mass	
(Figure	4G)	was	lower	in	Kcnj13ΔMC4RCre mice as a result of the 
increase in adipose mass.
Glucose	utilisation	was	assessed	by	an	IP	glucose	tolerance	test	
(GTT) in female mice at 28 weeks of age. The 2 mg kg‐1 dosage of 
glucose	 was	 adjusted	 in	 proportion	 to	 lean	 body	 mass.	 Although	
all genotypes initially responded to the bolus of glucose similarly 
(Figure	4H,I),	Kcnj13ΔMC4RCre mice showed impaired glucose me‐
tabolism	from	45	to	120	minutes	 (Figure	4J).	 Impaired	glucose	dis‐
posal was also observed in experiments using lean 11‐week‐old 
female Kcnj13ΔMC4RCre mice, relative to control Kcnj13 fl/fl mice 
(data not shown).
To attempt to accentuate the physiological response to the dele‐
tion	of	Kir7.1	in	MC4R	cells,	male	and	female	animals	of	all	four	geno‐
types	were	placed	on	a	HFD.	Mice	were	acclimated	to	single	housing	
at	8‐10	weeks	old	and	switched	from	chow	to	HFD	at	10‐13	weeks	
of age, during which time intake and growth were monitored weekly 
for	3	months.	A	clear	obesogenic	effect	of	 the	Cre	 transgene	was	
apparent in genotypes with or without Kcnj13 under these condi‐
tions, perhaps as a result of a reduction of functional MC4R result‐
ing from the method of Cre expression, requiring cleavage of an 
MC4R‐Cre fusion protein expressed under the control of the endog‐
enous	MC4R	promoter	(see	Supporting	information,	Figure	S1).	This	
method may result in the reduced expression of MC4R protein, and/
or	a	MC4R	protein	with	reduced	activity,	as	a	result	of	the	small	t2A	
peptide	fragment	that	remains	at	the	end	of	the	MC4R.	Nonetheless,	
the increased weight of male and female Kcnj13ΔMC4RCre mice was 
apparent	compared	to	MC4R‐Cre	controls.	A	mixed	linear	effect	sta‐
tistical	model,	 comprising	 an	 alternative	 to	ANOVA	with	 repeated	
measures, was used to analyse the growth curves. This modelling 
tool determined that the male Kcnj13ΔMC4RCre weight gain profiles 
(Figure	5A)	 are	 significantly	 greater	 than	 the	 Kcnj13+/+;MC4RCre 
controls.	 Female	 weight	 gain	 tended	 to	 be	 higher,	 and	 was	 also	
significantly	 different	 on	HFD	using	 Student’s	 t tests at individual 
time	points	from	70	to	84	days	(Figure	5C).	We	were	unable	to	mea‐
sure	an	effect	of	any	genotype	on	food	intake	(Figure	5B,D).	After	
consuming	 a	 HFD	 for	 3	months,	 there	 is	 a	 significant	 increase	 in	
fat mass in both Kcnj13ΔMC4RCre and Kcnj13+/+;MC4RCre groups 
(Figure	5E‐H);	 however,	 we	 were	 unable	 to	 measure	 an	 effect	 of	
Kir7.1	deletion,	possibly	as	a	result	of	the	significant	background	ef‐
fect	of	the	Cre	transgene	(Figure	5E‐H).
We	next	 tested	glucose	utilisation	by	 IPGTT.	Glucose	doses	at	
1 mg kg‐1	were	adjusted	in	proportion	to	lean	mass.	Despite	the	lack	of	
a measurable difference in adipose mass between Kcnj13ΔMC4RCre 
and Kcnj13+/+;MC4RCre mice, male and female Kcnj13ΔMC4RCre 
mice have significantly reduced glucose tolerance compared to all 
control strains, including Kcnj13+/+;MC4RCre	(Figure	5I‐L).
4  | DISCUSSION
MC4R is known to signal through the Gαs‐cAMP	signalling	pathway	
in cell assays and in vivo.29,37 However, our data on MC4R signalling 
in a hypothalamic slice preparation from the mouse suggested that 
the	MC4R	depolarises	neurones	in	the	PVN	via	G	protein‐independ‐
ent	regulation	of	the	inward	rectifier	Kir7.1.32 To assess the potential 
physiological	 role	of	 this	MC4R‐Kir7.1	signalling	pathway,	we	used	
Cre‐loxP	technology	to	delete	Kir7.1	from	MC4R‐expressing	cells	in	
the mouse, and investigated the consequences on MC4R signalling, 
as well as on MC4R‐mediated physiological responses.
Homozygous	loss	of	Kir7.1	is	known	to	cause	degenerative	eye	
diseases such as snowflake vitreoretinal degeneration and Leber 
congenital amaurosis 38,39 in humans, and a pigmentary defect in 
the jaguar zebrafish,40 and thus we anticipated being able to con‐
duct	our	studies	 in	 the	global	Kir7.1	knockout	mouse.	Surprisingly,	
however,	we	discovered	that	homozygous	deletion	of	Kir7.1	 in	the	
mouse caused perinatal lethality. Histological analysis demonstrated 
stunted lung and kidney development, as well as reduced body mass 
(see	Supporting	 information,	Figure	S2),	and	this	same	finding	was	
reported by another laboratory.35	It	is	unclear	why	Kir7.1	is	an	essen‐
tial developmental gene in the mouse but not zebrafish or humans, 
although the observation suggests variable physiological functions 
of this channel in different species.
After	 proceeding	 through	 a	 breeding	 strategy	 to	 obtain	 ani‐
mals with a floxed Kcnj13 allele, we generated animals with MC4R‐
site‐specific	 deletion	 of	 Kir7.1.	 Because	 Kir7.1	 is	 expressed	 at	
very low levels in the sparsely distributed MC4R neurones,32 we 
were	 unable	 to	 readily	 validate	 the	 absence	 of	Kir7.1	mRNA	 from	
MC4R	 neurones.	Recording	 from	MC4R	 labelled	 cells	 in	 the	 PVN	
is a well‐established tool for characterising MC4R firing activity.41 
Likewise, the depolarisation signature of MC4R cells via closure of 
Kir7.1	has	been	defined	 in	 the	slice	preparation.32 Using this func‐
tional	 assay,	we	 observed	 depolarisation	 of	 PVN	MC4R	 neurones	
from Kcnj13+/+;MC4RCre mice in response to α‐MSH	 (Figure	1A).	
By	contrast,	with	the	deletion	of	Kir7.1	 in	MC4R	PVN	neurones	 in	
Kcnj13ΔMC4RCre mice, α‐MSH‐induced depolarisation was no longer 
observed	(Figure	1B),	 supporting	 the	 hypothesis	 that	 Kir7.1	 is	 re‐
quired for α‐MSH‐induced	depolarisation	of	PVN	MC4R	neurones	
in the slice preparation. We have not surveyed this requirement for 
Kir7.1	in	other	MC4R	neurones	depolarised	by	α‐MSH.	Furthermore,	
we	do	not	know	how	depolarisation	of	PVN	MC4R	neurones	in	the	
slice preparation correlates with the physiological sequelae of MC4R 
activation	in	vivo.	Interestingly,	although	administration	of	MC4R	ag‐
onists	rapidly	inhibits	food	intake	(Figure	2),	inhibition	of	food	intake	
via	optogenetic	or	chemogenetic	activation	of	POMC	neurones42,43 
has a latency of several hours. Thus, it is possible that activation of 
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MC4R neurones in a slice preparation reflects pharmacological but 
not necessarily physiological activation of the MC4R.
To	investigate	the	role	of	Kir7.1	in	mediating	the	pharmacological	
response to melanocortin agonist in vivo, we began by quantifying 
the feeding response on regular chow in response to an anorexigenic 
dose of exogenously administered α‐MSH	analogue,	LY2112688.	No	
significant difference is observed in baseline daily chow consump‐
tion in control vs Kcnj13ΔMC4RCre	mice	(Figure	2A).	Although	food	
intake	was	potently	inhibited	by	IP	delivery	of	LY2112688	in	animals	
with	 intact	 Kir7.1	 in	MC4R	 cells,	male	 and	 female	 animals	 lacking	
Kir7.1	exhibited	a	reduced	responsiveness	to	LY2112688	throughout	
the study, and also exhibited a greatly reduced duration of response. 
Specifically,	 animals	 lacking	 Kir7.1	 in	 MC4R	 cells	 lost	 LY2112688	
responsiveness typically by 12 hours, whereas control strains sus‐
tained	responsiveness	for	24‐40	hours	(Figure	2A‐C).	These	results	
suggested that the sustained activity of an administered MC4R ag‐
onist	requires	Kir7.1.	Experiments	using	viral	knockdown	of	Kir7.1	in	
the	PVN	produced	very	 similar	 findings,	 indicating	 that	 the	effect	
was	a	result	of	the	acute	loss	of	function	of	Kir7.1	in	PVN	neurones,	
rather than a developmental defect.
This study parallels prior work using a Tl+	flux	assay	in	HEK293	
cells	expressing	MC4R	and	Kir7.1	 to	characterise	 the	regulation	of	
ion	flux	through	Kir7.1	mediated	by	MC4R.44 These data suggested 
that	the	G	protein‐mediated	cAMP	response	peaks	rapidly	after	α‐
MSH	exposure,	whereas	 inhibition	 of	 Tl+	 flux	 through	Kir7.1	 con‐
tinued	 long	 after	 the	 cAMP	 response	 ebbed.32	 Although	our	 data	
clearly demonstrated pharmacological defects in response to me‐
lanocortin	agonists	 in	the	absence	of	Kir7.1,	 it	would	also	be	inter‐
esting to examine the effects of chronic optogenetic stimulation of 
POMC	 neurones	 in	 the	Kcnj13ΔMC4RCre mouse, given the delayed 
anorexigenic response observed in this assay.
AgRP	 engages	 the	MC4R	 at	 high	 affinity	 but	 does	 not	 couple	
the receptor to G proteins or stimulate arrestin recruitment.45 Thus, 
when	we	determined	that	AgRP	stimulates	MC4R‐dependent	open‐
ing	of	Kir7.1,32	we	predicted	that	AgRP	was	a	biased	agonist,	signalling	
specifically	via	Kir7.1.	We	thus	anticipated	that	the	Kcnj13ΔMC4RCre 
would have a reduced physiological response to the inverse agonist 
AgRP	as	well.	However,	a	preliminary	study	demonstrated	that	i.c.v.	
delivery	of	AgRP	to	the	hypothalamus	induced	similar	hyperphagia	
and	 4	days	 of	 weight	 gain	 in	Kcnj13ΔMC4RCre and control mice 
(see	 Supporting	 information,	 Figure	 S4).	 Thus,	 in	 contrast	 to	 our	
hypothesis,	 AgRP	may	 not	 require	 Kir7.1	 for	 normal	 signalling.	Of	
course, these studies were also limited by virtue of being pharma‐
cological in nature, and additional studies will need to be conducted 
to determine whether a compensatory signalling pathway has been 
activated	 in	 this	 knockout	model,	 such	as	AgRP	activation	of	ERK	
phosphorylation.46,47	Other	explanations	include	the	possibility	that	
(i)	AgRP	functions	exclusively	as	an	inverse	agonist	and	competitive	
antagonist of MC4R driven Gαs	signalling	or	(ii)	AgRP	also	signals	via	
an as yet unidentified mechanism.48‐50
Not	only	is	MC4R	widely	expressed	in	the	CNS,	but	also	sites	of	
peripheral expression have been detected, namely in the peripheral 
nervous system and enteroendocrine L cells.36,37,51,52 Using an assay 
for	detecting	MC4R‐dependent	L‐cell	release	of	PYY	in	response	to	
exogenous administration of the α‐MSH analogue LY2112688, we 
found	that	the	absence	of	Kir7.1	in	MC4R	cells	has	no	effect	on	PYY	
release	 (Figure	3).	 These	 data	 clearly	 showed	 that	MC4R	 induces	
PYY	release	in	a	Kir7.1‐independent	manner,	emphasising	that	there	
are multiple modes of MC4R signalling, and that some physiological 
MC4R	signalling	events	are	Kir7.1‐independent.	Elevation	of	cAMP	
in	L	cells	has	been	demonstrated	to	stimulate	PYY	release.36
Deletion	 or	 haploinsufficiency	 of	 the	MC4R	 results	 in	 a	 rapid	
onset of phenotypes, most prominently early onset obesity char‐
acterised by both hyperphagia, reduced energy expenditure and 
hyperinsulinaemia, observable by 8 weeks of age.8,53,54 To address 
the	physiological	phenotype(s)	of	site‐specific	loss	of	Kir7.1	in	MC4R	
cells, we investigated the weight gain profile, caloric consumption, 
body mass composition, linear growth and glucose metabolism of 
Kcnj13ΔMC4RCre	mice	maintained	 on	 normal	mouse	 chow.	 Initially,	
at the 9‐15‐week time points, we observed no change in body 
weight, body composition or metabolism in these mice. However, 
because mice were measured beyond 15 weeks, we observed that 
the Kcnj13ΔMC4RCre mice tended to gain more weight than control 
genotypes,	particularly	in	females.	At	1	year	of	age,	we	observed	in‐
creased weight in Kcnj13ΔMC4RCre male and female mice compared 
to Kcnj13 fl/fl, Kcnj13+/+;MC4RCre and Kcnj13+/+;MC4R+/+ mice; more‐
over, female Kcnj13ΔMC4RCre mice gained weight more rapidly than 
males	(Figure	4A,B).	It	was	interesting	to	note	a	large	effect	of	Kir7.1	
loss	on	linear	growth	at	30	weeks	of	age	(Figure	4C‐D),	reminiscent	
of an effect seen on MC4R deletion. The late onset weight gain was 
clearly	a	 result	of	 increased	adipose	mass	 (Figure	4F)	and	not	 lean	
mass	 (Figure	4G),	 although	 it	 was	 not	 accompanied	 by	 any	 mea‐
surable	hyperphagia	 (Figure	4E).	The	 lean	mass	adjusted,	 low	dose	
glucose tolerance test indicated deterioration of peripheral glucose 
metabolism in Kcnj13ΔMC4RCre mice, associated with significant fat 
accrual	(Figure	4J‐L).	MC4R	signalling	regulates	glucose	homeostasis	
in addition to excess adipose mass animals, both of which may have 
contributed to defective glucose utilisation shown here.7	It	is	possi‐
ble that hyperphagia exists, although it is too small to be detected, in 
parallel with the very slow late onset obesity.
To	potentially	accelerate	the	effects	of	Kir7.1	deletion,	we	con‐
ducted	 similar	 experiments,	 placing	 mice	 on	 a	 HFD.	 Notably,	 the	
expression of MC4R‐t2a‐Cre‐recombinase alone had an obesogenic 
effect	on	HFD	fed	mice	(Figure	5A,C).	Given	the	morbid	early	onset	
obesity arising from a 50% reduction in MC4R expression in mice or 
humans,	 even	a	 very	 small	 reduction	of	MC4R	mRNA	production,	
or a reduced production or function of the MC4R protein result‐
ing from, for example, inefficient cleavage of the t2a site needed 
for release of Cre‐recombinase from the MC4R‐Cre fusion protein, 
could explain the obesity seen in Kcnj13+/+;MC4RCre mice fed high‐fat 
chow. Similarly, it is possible that the 18‐22 amino acid carboxy‐ter‐
minal extension on the MC4R protein, resulting from cleavage of 
MC4R and Cre‐recombinase, produced an MC4R with slightly re‐
duced activity. However, these remain hypotheses because we have 
no	data	available	regarding	the	MC4R	mRNA	or	protein	made	by	the	
MC4R‐t2a‐Cre‐recombinase construct.
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Nonetheless,	 when	 Kir7.1	 was	 ablated	 from	 MC4R	 cells,	 male	
and female mice were more sensitive to diet‐induced weight gain 
than the Kcnj13+/+; MC4RCre controls	 (Figure	5A,	 C).	 This	 did	 not	
appear to be the result of a sustained measurable hyperphagic re‐
sponse	 (Figure	5B,	D).	A	 comparison	of	 body	mass	 composition	by	
NMR	reveals	a	significant	increase	in	fat	mass	in	both	male	and	female	
Kcnj13ΔMC4RCre animals compared to Kcnj13+/+ and Kcnj13 fl/fl con‐
trols but not compared to Kcnj13+/+;MC4RCre	(Figure	5E‐H).	 Given	
the significant increase in total weight, we hypothesise that the lack 
of a difference in fat mass in Kcnj13ΔMC4RCre animals vs controls may 
be	the	result	of	a	lack	of	sensitivity	of	the	whole	animal	NMR	method.
After	mice	had	matured	on	a	HFD,	a	glucose	tolerance	test	was	
conducted	to	test	glucose	utilisation.	A	low	glucose	dose	(1	mg	kg‐1) 
adjusted	 to	 lean	 mass	 was	 used	 because	 mice	 on	 a	 HFD	 already	
have compromised glucose homeostasis.55 Here, the Cre‐driver line 
had no intermediate phenotype, whereas the Kcnj13ΔMC4RCre male 
and female mice had perturbed tolerance to glucose as confirmed 
by	a	 significant	 increase	 in	 area	under	 the	 curve	 (Figure	5I‐L).	The	
autonomic nervous system governs central glycaemia via 
its	 two	 arms:	ChATMc4r	expressing	 sympathetic	 neurones	
and	Phox2bMc4r expressing parasympathetic neurones.53 Mice lack‐
ing MC4R present with hyperglycaemia and hyperinsulinaemia that 
is	 further	 exacerbated	 during	 fat	 accrual	 into	 maturity.	 Although	
parasympathetic nervous system outflow stimulates insulin release, 
sympathetic	 nervous	 system	 outflow	 via	 ChATMc4r neurones has 
been demonstrated to modulate glycemic tone.17 The deteriorating 
weight maintenance and glucose intolerance in Kcnj13ΔMC4RCre mice 
suggests	that	Kir7.1	may	also	augment	MC4R	signalling	in	autonomic	
nervous system pathways regulating glucose homeostasis.
The data reported in the present study show a measurable re‐
quirement	 for	 Kir7.1	 in	 MC4R	 neurones	 for	 pharmacological	 re‐
sponses	to	melanocortin	agonists	but	not	antagonists.	 In	particular,	
Kir7.1	may	be	required	for	sustained	responses	to	pharmacotherapy	
with	melanocortin	agonists	such	as	setmelanotide.	It	will	be	informa‐
tive to determine whether the delayed anorexigenic effect of optoge‐
netic	stimulation	of	POMC	neurones	requires	Kir7.1.	Likewise,	given	
the	apparent	role	of	Kir7.1	in	sustained	anorexia,	it	may	be	informative	
to	investigate	the	role	of	Kir7.1	in	mediating	the	demonstrated	role	of	
MC4R signalling in disease cachexia in the mouse.56 Similarly, other 
physiological responses to melanocortins, such as those involved in 
the	control	of	glucose	homeostasis,	may	depend	on	Kir7.1.
We	were	surprised	to	note	the	very	modest	effect	of	Kir7.1	on	
body weight, as well as the divergence of the phenotype from that 
seen in MC4R knockout mice and patients with MC4R mutations. 
Indeed,	all	mutations	 leading	to	defective	MC4R	signalling,	 includ‐
ing	mutations	in	MC4R,	POMC,	deletion	of	GαS in MC4R cells and 
even	overexpression	of	AgRP,	lead	to	a	similar	melanocortin	obesity	
phenotype, characterised by early onset severe obesity, with hy‐
perphagia,	increased	linear	growth	and	increased	lean	mass.	A	very	
different phenotype, involving modest late onset obesity with no 
measurable hyperphagia, increased linear growth and no increase in 
lean	mass,	was	instead	observed	in	mice	lacking	Kir7.1	in	MC4R	cells.	
There are many potential explanations for these findings, including 
changes	that	compensate	early	on	for	the	absence	of	Kir7.1.	Recently,	
a rather dramatic example was reported illustrating the tremendous 
compensatory plasticity of the melanocortin circuits in response to 
early developmental gene knockout.57	Deletion	 of	 leptin	 receptor	
from	AgRP	neurones	is	found	to	produce	only	a	minor	obesity	and	
diabetes phenotype,58 relative to global leptin receptor deletion. By 
contrast,	CRISPR‐mediated	deletion	of	the	gene	in	AgRP	neurones	
in adult animals produced a morbid obesity syndrome almost par‐
alleling that seen in the db/db mouse.57 Even more relevant to the 
present	study,	 leptin	hyperpolarises	neurones	by	opening	the	KATP 
channel.59	 Although	 global	 deletion	 of	 the	 Kir6.2	 subunit	 of	 this	
channel had a limited effect on glucose homeostasis and no obe‐
sogenic effect,60,61	CRISPR‐mediated	mutagenesis	of	Kir6.2	in	AgRP	
neurones alone yielded a morbid obesity syndrome with diabetes.57 
Thus, it is possible that a wholly different phenotype may be seen 
upon	deletion	of	Kir7.1	in	the	adult	mouse.
Alternatively,	the	results	reported	in	the	present	study	may	in‐
dicate	that	Kir7.1	plays	a	very	specific	and	limited	role	in	the	phys‐
iological	 functioning	of	 the	MC4R.	Additionally,	 the	data	obtained	
do not rule out the possibility that the phenotype results from a 
minor developmental alteration in a subset of MC4R neurones. 
Furthermore,	we	provide	a	direct	example	of	a	physiologically‐medi‐
ated	MC4R	pathway,	PYY	release,	from	L	cells,	which	appears	to	be	
Kir7.1‐independent.	 Interestingly,	 irrespective	 of	 the	 physiological	
role(s)	for	Kir7.1	in	MC4R	signalling,	the	present	study	demonstrates	
a	significant	pharmacological	effect	of	Kir7.1	in	vivo	and	in	the	slice	
preparation. These data may thus be important for the ongoing chal‐
lenge with respect to the development of therapeutics acting at the 
MC4R, further highlighting the complexities of MC4R signalling that 
remain to be solved.
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